The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	16.21B +4.1%
Revenue (ttm)	38.86B +16.0%
Net Income	2.56B +7.2%
EPS	12.11 +7.2%
Shares Out	211.60M
PE Ratio	6.32
Forward PE	n/a
Dividend	3.50 (4.57%)
Ex-Dividend Date	Nov 19, 2025

Volume	202,746
Average Volume	228,289
Open	n/a
Previous Close	76.60
Day's Range	76.30 - 77.00
52-Week Range	67.90 - 85.90
Beta	0.08
RSI	53.18
Earnings Date	Apr 29, 2026

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacturing, marketing, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and ...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,025
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In fiscal year 2025, The ACME Laboratories's revenue was 35.94 billion, an increase of 12.54% compared to the previous year's 31.93 billion. Earnings were 2.43 billion, a decrease of -1.12%.